Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Privosegtor - Oculis Pharma

Next Previous
Drug Profile

Privosegtor - Oculis Pharma

Alternative Names: ACT-01; BN-201; G-79; OCS 05

Latest Information Update: 19 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bionure
  • Developer Bionure; Oculis Pharma
  • Class Anti-inflammatories; Antiglaucomas; Eye disorder therapies; Neuroprotectants; Peptides; Small molecules
  • Mechanism of Action Brain derived neurotrophic factor agonists; Insulin-like growth factor I stimulants; Neuron modulators; Serum-glucocorticoid regulated kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Optic neuritis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Optic neuritis
  • Preclinical Glaucoma; Neurotrophic keratopathy
  • No development reported Multiple sclerosis; Neuromyelitis optica

Most Recent Events

  • 08 May 2025 Oculis Pharma intends to initiate a registrational trial for acute optic neuritis in first half of 2026
  • 08 May 2025 Oculis Pharma plans to conduct an end-of-phase II meeting with the US FDA to discuss the phase II ACUITY trial results and registrational development program for Optic neuritis, in the third quarter of 2025
  • 08 May 2025 Pre-IND discussions with the US FDA are planned for Multiple sclerosis in second half of 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top